Extended Data Fig. 3: Percent change in target lesion measurement from baseline over time per RECIST v1.1 in patients in the part 2a 1.8 mg kg−1 2L cohort. | Nature Medicine

Extended Data Fig. 3: Percent change in target lesion measurement from baseline over time per RECIST v1.1 in patients in the part 2a 1.8 mg kg−1 2L cohort.

From: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Extended Data Fig. 3: Percent change in target lesion measurement from baseline over time per RECIST v1.1 in patients in the part 2a 1.8 mg kg−1 2L cohort.The alternative text for this image may have been generated using AI.

2L, second line; CR, complete response; PD, progressive disease; PR, partial response; RECIST v.1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SCLC, small cell lung cancer; SD, stable disease.

Back to article page